<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25150">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02029014</url>
  </required_header>
  <id_info>
    <org_study_id>LAA v1.1</org_study_id>
    <nct_id>NCT02029014</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of LAmbre LAA Closure Device for Treating AF Patients Who Cannot Take Warfarin</brief_title>
  <official_title>Evaluation of Safety and Efficacy of the New Generation of Left Appendage Closure With the LAmbre Device in AF Patients Not Suitable for Use of Warfarin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lifetech Scientific (Shenzhen) Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lifetech Scientific (Shenzhen) Co., Ltd.</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the efficacy, safety and performance of LAmbre left
      atrial appendage closure system in patients with non-valvular atrial fibrillation who cannot
      be treated with Warfarin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful sealing of the LAA</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Component events</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>death, thromboembolism, device related complication and MACCE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACCE</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>all-cause death, stroke, cardiac tamponade and renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication at puncture site</measure>
    <time_frame>One year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device performance assessed by TEE/TTE</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Device migration/embolization Regurgitation Perivalvular leak</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>LAmbre closure system</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LAA closure system</intervention_name>
    <arm_group_label>LAmbre closure system</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt;=18, CHADS2 score&gt;=1

          -  Patients cannot be treated long-term with Warfarin

          -  Eligible for clopidogrel and aspirin

          -  Provide written informed consent and agree to comply with required follow-ups

        Exclusion Criteria:

          -  Need to take Warfarin

          -  Presence of rheumatic, degenerative or congenital valvular heart diseases

          -  Early stage or paroxysmal AF

          -  Symptomatic patients with carotid artery disease (such as carotid stenosis&gt;=50%)

          -  Heart failure NYHA grade IV

          -  Recent 30 days stroke or TIA

          -  Presence of active sepsis or endocarditis

          -  Cardiac tumors or other malignancy with estimated life expectancy &lt;2 years

          -  Abnormal blood test; renal disfunction

          -  LAA removed or heart implant patients

          -  Patients have planned electrophysiological ablation or cardioversion 30 days post
             implantation of the LAmbre system

          -  Patients have history of mechanical prosthesis operation

          -  Patients who are pregnant, or desire to be pregnant during the during the study

          -  Participation in other trials

          -  A known allergy to nitinol

          -  Patients will not be able to complete the trial

        Esophageal ultrasonic exclusion criteria:

          -  LAA Ostium &lt;=12mm or &gt;=30mm

          -  LVEF &lt;30%

          -  Presence of thrombus in the heart

          -  High risk PFO

          -  Mitral valve stenosis (valve area &lt;2 cm2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Congxin Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>People's Hospital of Wuhan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Liu, MD</last_name>
    <phone>+86 10 6595 6828</phone>
    <phone_ext>806</phone_ext>
    <email>davidliu@coremed.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>People's Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Liu, MD</last_name>
      <phone>+86 10 6595 6828</phone>
      <phone_ext>806</phone_ext>
      <email>davidliu@coremed.com.cn</email>
    </contact>
    <investigator>
      <last_name>Congxin Huang, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 16, 2014</lastchanged_date>
  <firstreceived_date>January 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LAmbre</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
